Having breast cancer in your 20s or 30s brings a unique set of considerations – and agonies https://t.co/1dclD5ZmNP ...

So, if you take this risk assessment test and you get above 20%. Um, what are you supposed to do. And and why is 20% the marker.So, our lifetime risk as women in America is 13%. Once it's above 20%, that means we want to be more proactive to find it because we might not just find it if we only do the annual screening tests. So the supplemental screening typically would be a breast MRI and then going forward you would do a mammogram and ultrasound once a year. Six months later you would do an MRI which would ...

Core Insights - RadNet, Inc. has partnered with Regal Medical Group, Lakeside Community Healthcare, and ADOC Medical Group to include its AI-powered Early Breast Cancer Detection (EBCD) program in their health plans, enhancing access to advanced diagnostic services for patients [1][3][7] Group 1: Partnership and Program Implementation - The medical groups involved are located in Southern California, covering counties such as Los Angeles, Ventura, Orange, San Bernardino, Riverside, and San Diego, and will provide EBCD services to all eligible mammogram patients [2][7] - RadNet will initiate a patient outreach program to improve compliance with annual mammography screening guidelines by actively contacting eligible patients [2][3] Group 2: Commitment to Early Detection - Dr. Howard Berger, CEO of RadNet, emphasized the importance of early breast cancer detection, noting that one in eight women will develop breast cancer in their lifetime, making early detection critical for optimal treatment [3] - The EBCD program aims to detect breast cancer earlier than traditional methods, potentially reducing treatment needs and improving patient outcomes [3][4] Group 3: Impact on Patient Care - Will Jukes, Senior VP of Regal Medical Group, stated that the EBCD program will enhance early cancer detection and streamline the screening process, positively affecting patient outcomes [4] - The collaboration is expected to increase annual compliance with screening guidelines, showcasing a commitment to innovative healthcare solutions [4][7] Group 4: Market Position and Reach - RadNet operates a network of 401 outpatient imaging centers across several states, including California, and is a leading provider of diagnostic imaging services in the U.S. [8] - The partnership with major health insurance carriers will expand access to quality care for nearly 600,000 members in Southern California [7][8]

After Emily Kwan finished breast cancer treatment, she decided she didn’t want to wait anymore to live the way she wanted: “I was thinking that I don’t know how long I’ll live and I want to enjoy what I can right now” 🔗 https://t.co/0MmWu2fBjb https://t.co/ca7ZBbVoxv ...

Year-end 2024 Business Update NASDAQ: ATOS www.atossatherapeutics.com Disclaimer • This presentation may contain certain forward-looking statements related to or Atossa Therapeutics, Inc. (the "Company") that involve risks and uncertainties. • Actual results and events may differ significantly from results and events discussed in forward-looking statements. • Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" in the Company's Annual ...

Breast Cancer Statistics and Screening Challenges - Globally, breast cancer caused 670,000 deaths in 2022, with 11,500 deaths in the UK, equating to 32 deaths per day, and cases are predicted to rise to 70,000 by 2040 [1] - While death rates are falling by 44% due to interventions, better screening, and treatments, low screening uptake remains a concern, especially among underserved populations [1] - NHS backlogs, exacerbated by decades of underfunding and COVID-19, contribute to reduced resources and disproportion between screenings needed and available radiologists and mammographic equipment [1] - Accessibility problems are significantly worse for underserved populations, with cultural unacceptability, invasiveness, fear of radiation, and pain deterring women from undergoing mammography [1] - A survey revealed that 21% of 2,000 women cited embarrassment and fear of pain as reasons for avoiding screening [1] Fingerprint-Based Breast Cancer Screening Innovation - A novel fingerprint-based test is proposed as a non-invasive, radiation-free, and painless alternative to mammography, bypassing NHS backlogs and resource constraints [1] - The technology utilizes mass spectrometry (MALDI) to analyze molecular patterns in fingerprints, identifying proteins indicative of an individual's state, including potential biomarkers for breast cancer [1] - Research demonstrated the ability to differentiate between male and female fingerprints with 86% accuracy by analyzing protein profiles [2] - A study involving 135 samples from 15 women showed that a machine learning algorithm could distinguish between early breast cancer, benign conditions, and metastatic cancer with 97.8% accuracy [2] - The fingerprint test aims to reduce NHS costs, increase accessibility (potentially at GP practices or at home), improve compliance, and ultimately save lives [2]

Olema Pharmaceuticals (OLMA) 2025 Conference June 04, 2025 11:40 AM ET Speaker0 Good afternoon. How are you? Thank you for joining us on the next panel discussion here. I am very fortunate to have the CEO of Olima Pharmaceuticals here, Sean Bowen. Sean is continuing to work on developing and executing on his breast cancer drug, palazestrin. Obviously we just came away from ASCO and continue to learn more about the developments in breast cancer. And so I would love, Sean, maybe just to give a snapshot view. ...

Poster Presentation Details Title: OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care endocrine therapy for patients with ER+, HER2- advanced breast cancer after endocrine and CDK4/6 inhibitor therapy Abstract Number: TPS1131 Poster Number: 104b Poster Session: Breast Cancer – Metastatic Date/Time: June 2, 2025 from 9:00am–12:00pm CT / 10:00am–1:00pm ET "Metastatic breast cancer treatment continues to be challenged by resistance mechanisms resulting i ...

Core Insights - The partnership between Susan G. Komen, Tokio Marine HCC (TMHCC), and Nelly Korda aims to raise awareness and funds for breast cancer research and support [1][5][6] Group 1: Partnership and Contributions - TMHCC will donate $5,000 for every birdie and $10,000 for every eagle scored by Nelly Korda during the tournament, with a guaranteed minimum donation of $50,000 [3] - Additional donations from TMHCC include $25,000 for a hole in one, $100,000 for a three-stroke win, $500,000 for a four-stroke win, and $1 million for a five or more stroke win [4] Group 2: Breast Cancer Statistics - An estimated 316,950 women in the U.S. will be diagnosed with invasive breast cancer for the first time in 2025, with 42,170 expected to succumb to the disease [2] Group 3: Organizational Background - TMHCC is part of the Tokio Marine Group, which has a market capitalization of $74 billion as of March 31, 2025, and holds strong financial ratings from S&P Global Ratings, AM Best, and Fitch Ratings [8] - Susan G. Komen is the leading nonprofit organization focused on breast cancer, providing comprehensive support and advocacy for patients while driving research for breakthroughs [10]

Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in combination with palbociclib and fulvestrant more than doubled progression-free survival in the first-line setting1The Itovebi-based regimen also demonstrated a statistically significant and clinically meaningful benefit in overall survival (OS) in the final OS analysisFinal OS data will be presented in an oral session at the 2025 American Society of Clinical Oncology Annual Meeting Basel, 23 May 2025 - Roche (SIX: RO ...